肩袖损害可以天然愈合？Smith & Nephew拟2.1亿美元收买Rotation Medical，与你一同见证。
私募融资 & IPO
概要：坐落美国纽约的生物科技公司Y-mAbs宣告取得5000万美元出资，用于其癌症抗体项目burtomab和naxitamab的后期临床实验。这两项药物在斯隆-凯特琳癌症中心（Memorial Sloan-Kettering Cancer Center，简称MSK）被最早发现，将用于医治癌症中的稀有病如儿童神经母细胞瘤。继本年1月各大安排竞相出资的1200万美元之后，该公司在美国临床肿瘤学会年会（American Society of Clinical Oncology，简称ASCO）会议上宣告其药物burtomab在患有儿童神经母细胞瘤和柔脑膜搬运的儿童身上取得活跃的实验成果。
Y-mAbs raises $50M funding to propel cancer duo into late-stage testing
Oct 25, 2017
Y-mAbs Therapeutics has raised $50 millionfrom private investors to fund late-stage trials of two antibodies—originally discovered at Memorial Sloan-Kettering Cancer Center (MSK)—with potential inthe treatment of rare cancers. The New York biotech’s CEO Claus Møller, M.D.,says the cash—from existing investors and new backer HBM Healthcare Investments—will “enable us to focus on bringing our lead compounds, burtomaband naxitamab, through the final steps of the regulatory pathway towards approval.”
The fundraising is the second for Y-mAbs thisyear after it raised $12 million in an oversubscribed offering in January, andcomes after the biotech reported positive clinical results with burtomab inchildren with neuroblastoma and leptomeningeal (brain) metastases at thisyear’s ASCO conference. Neuroblastoma is a primary focus for Y-mAbs,which was set up three and half years ago by Thomas Gad after his daughter was treated for neuroblastoma at MSK. This type of cancer mainly affects babies and young children—with around 700 cases a year in the U.S.—and typically starts inthe adrenal glands but can quickly spread to other organs. HBM’s CEO Andreas Wicki said Y-mAbs’ approachto immunotherapy “shows great promise and will further advance innovation andproduct development in the pediatric oncology field.”
1. 肩袖损害可以天然愈合？Smith & Nephew将用2.1亿美元收买Rotation Medical，与你一同见证
概要：英国医疗公司Smith & Nephew宣告即将收买美国安排再生研制商Rotation Medical。后者首要进行肩袖损害相关疗法的立异研制，在患者进行关节内镜辅佐查看的过程中，植入邮票巨细的、从牛的阿基里斯腱中提取的胶原蛋白生物传感移植体系，然后增强人体天然愈合才能，促进肩袖部位安排再生。这一移植体系在2014年取得了FDA的同意。Smith & Nephew方面表明，Rotation Medical将会强化公司的立异才能，瞄准从未被真实处理的肩袖损害市场需求。在收买之后，Smith& Nephew方案使用本身的运动药物出售团队和Rotation Medical本身的出售团队在全球推行该产品，并争夺取得在欧盟区域的批阅答应。
Smith & Nephew to acquire Rotation Medical for up to $210M
Oct 23, 2017
Smith & Nephew has agreed to acquiretissue regeneration player Rotation Medical for $125 million in cash upfront. Another $85 million is on the table if certain financial milestones are achieved. Rotation Medical is dedicated to transforming how rotator cuff tears are treated. The Plymouth, Minnesota-based company developed a collagen-based bioinductive implant derived from bovine Achillestendon. About the size of a postage stamp, the implant is delivered arthroscopically. It is designed to foster the growth of new, tendonlike tissue in the rotator cuff and earned FDA clearance in 2014. The treatment boosts the body’s natural healing response and has the potential to stop tears from getting worse andreduce the likelihood of retears, Smith & Nephew said in a statement. Rotator cuff tears are typically treated withsurgery, but many people delay surgery until the injury and pain have progressed, Rotation Medical says. While this allows patients to put off the long rehabilitation period and lifestyle changes that accompany recovery, italso makes it more difficult to repair the tear. “Rotation Medical furthers our strategy toinvest in disruptive technologies that accelerate the transformation of Smith& Nephew to higher growth,” said Smith & Nephew CEO Olivier Bohuon inthe statement. “The Rotation Medical Rotator Cuff System is an innovativetechnology serving unmet clinical needs. It is highly complementary to ourSports Medicine portfolio and provides a compelling new treatment option forour customers.” Smith & Nephew will sell the productthrough its sports medicine sales team, as well as through Rotation Medical’ssales force. The company also plans to file for regulatory approval in the EU.
Stryker to acquire French spinal implant maker Vexim for $216m
Oct 25, 2017
Stryker (NYSE:SYK) yesterday acquired amajority stake in Vexim for roughly $216 million and plans to buy the rest ofthe French spinal implant maker today. Kalamazoo, Mich.-based Stryker paid €20($23.63) per share for Vexim’s stock and €3.91 ($4.62) per listed warrant, fora total equity value of €183 million, Vexim said. The deal is expected to close during the fourth quarter. “We are really excited by this transaction and enthusiastic about our future integration into Stryker’s interventional spinebusiness, which we view as highly complementary to Vexim. Stryker willsignificantly help us achieve our objective to become a global spine trauma leader, through consolidation of our European presence and expansion of our international footprint. We will benefit from Stryker’s broad customer base and commercial platform in back trauma surgery, enabling further acceleration inthe adoption of the SpineJack technology. Stryker is the ideal partner to lay the ground for Vexim business on the promising US market,” CEO Vincent Gardèssaid in prepared remarks.
Vexim’s clinical trial of its SpineJackdevice, compared with balloon kyphoplasty, is on track for a bid for 510(k)clearance in the U.S. next year, Gardès said. “As Vexim enters its next chapter of growth aspart of Stryker Corp., I would like to warmly thank our reference shareholdersTruffle Capital, which co-founded the company, Bpifrance and Kreaxi, all of which steadily supported Vexim over the years,” he said. “This transaction further illustrates the power of medtech radical innovation in France,” added Truffle CEO Dr. PhilippePouletty.
Lilly weighs spinoff of bulked up Elanco even as it beats Streetestimates in Q3
Oct 24, 2017
Already working to slim down with thousands ofjobbbbbb cuts, Eli Lilly announced on Tuesday it’s looking at options for animal health business Elanco that could include a sale. At the same time, the drugmaker reported Street-beating sales for the third quarter, prompting it to boost its guidance for the year. Lilly says it is “reviewing strategic alternatives” for Elanco the animal health business that it has considerably bulked up with its $5.4 billion deal for Novartis’ animal healthbusiness in 2014, followed by a 2016 acquisition of Vetmedica, from BoehringerIngelheim for $885 million. The company has “grown Elanco to a sizeand scale that now allows us to consider a variety of options to maximizefuture value,” CEO David Ricks said in a statement. Lilly said it might still keep the business but is also weighing an IPO or sale of Elanco. It’ll make an announcement on its decision by the middle of next year, according to its third-quarterearnings release. Overall, Lilly reported sales of $5.66 billionin the third quarter, a 9% increase over last year to beat consensus estimatesof $5.52 billion, even getting some benefit from insulin sales which have beenunder pressure from payers. Humalog beat sales estimates by $53 million. Lillyraised its 2017 sales guidance to $22.4 billion to $22.7 billion, from aprevious range of $22 billion to $22.5 billion. But third-quarter earnings took a hit on therecent large-scale slimdown the company announced that will cut 3,500 jobs inan effort to save $500 million in annual expenses. That move cost the drugmaker $1.2 billion up front. Reported EPS was 53 cents per share for the quarter,down 29% from the same period last year. Non-GAAP income and earnings per sharewere up 19% each versus last year’s third quarter. So far this year, Lilly’s Elanco has generated$2.3 billion in sales. A year ago, some market watchers wondered if Lilly might move to unload Elanco as the unit’s sales dragged. But former CEO JohnLechleiter defended the unit, saying it was important to diversify thedrugmaker’s revenues. Since taking the helm this year, new CEO Rickshas been on a turnaround mission, focusing on new drug launches and tweakingthe company to be more efficient.